NCT01159223 is a Phase 4 clinical trial of ATV/r in HIV Infections, sponsored by The HIV Netherlands Australia Thailand Research Collaboration.

Who is sponsoring NCT01159223?

NCT01159223 is sponsored by The HIV Netherlands Australia Thailand Research Collaboration.

What drugs are being tested in NCT01159223?

Interventions in NCT01159223: ATV/r.

What condition does NCT01159223 study?

NCT01159223 studies HIV Infections.

Is NCT01159223 still recruiting?

NCT01159223 is currently completed. Last updated 17 August 2016.

Last reviewed 2016-08-17 · How we verify

NCT01159223

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multicenter Randomized Study to Compare the Efficacy and Safety of Lower Dose Atazanavir /Ritonavir (ATV/r 200/100 OD) Versus Standard Dose (ATV/r 300/100 mg OD) in Combination With 2NRTIs in Well Virology Suppressed HIV-infected Adults

Completed Phase 4 Last updated 17 August 2016

What this trial tests

Phase 4 trial testing ATV/r in HIV Infections in 559 participants. Completed in 1 June 2015.

Timeline

1 May 2011

Primary endpoint
1 December 2014

1 June 2015

Quick facts

Lead sponsor	The HIV Netherlands Australia Thailand Research Collaboration
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	559
Start date	1 May 2011
Primary completion	1 December 2014
Estimated completion	1 June 2015
Sites	10 locations across Thailand

Drugs / interventions tested

ATV/r — full drug profile →

Conditions studied

HIV Infections — all drugs for HIV Infections →

Sponsor

The HIV Netherlands Australia Thailand Research Collaboration — full company profile →

Who can join

18 and older, any sex, with HIV Infections. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

noninferiority
Time frame: Dec. 2013
ATV/r 200/100 mg will be judged to be non-inferior to ATV 300/100mg if the lower limit of the 95% confidence interval for the difference in proportion of patients with virological response between the two groups does not exceed -10%

Sponsor's own description

This study will compare the efficacy and safety of ATV/r at either 200/100 mg or 300/100mg given daily in Thai patients in combination with 2NRTIs.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial.
Bunupuradah T, Kiertiburanakul S, Avihingsanon A, Chetchotisakd P, et al · · 2016 · cited 18× · PMID 27470026 · DOI 10.1016/s2352-3018(16)30010-8

Verify or expand the search:

Other trials of ATV/r

Trials testing the same drug.

NCT01903031 — Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART · Phase 2 · completed

Other recruiting trials for HIV Infections

Currently open trials in the same condition.

NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
NCT07235852 — Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention · NA · recruiting
NCT06665646 — Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad · Phase 1 · recruiting

Other The HIV Netherlands Australia Thailand Research Collaboration trials

Trials by the same sponsor.

NCT04552015 — Microneedles for Diagnosis of LTBI · NA · terminated
NCT03731559 — Efficacy, Safety and Pharmacokinetics of DTG with RIF · Phase 2 · recruiting
NCT03835832 — Self-Assessment Tuberculin Skin Test · completed
NCT03727152 — Switching From Protease Inhibitor/Ritonavir to Generic Single Tablet Regimen of Tenofovir Alafenamide/Emtricitibine/Dolu · Phase 3 · completed
NCT03037151 — Safety and Efficacy of Grazoprevir and Elbasvir for GT1ang GT6 With and Without HIV · Phase 4 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01159223 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The HIV Netherlands Australia Thailand Research Collaboration
Last refreshed: 17 August 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01159223.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing